Sentences with phrase «patient continues the therapy»

The patient continues the therapy until the infection has ran its course.

From four months to six months, patients continued therapy and began light strengthening exercises.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Lowering the dietary intake of FODMAPs continues to be the first line therapy for patients experiencing GI symptoms.

In a physical therapy clinic, patients with neck pain despise doing neck exercises, but they know, if not completed, their neck pain will continue.

It is vital that therapy / treatment be continued and not stopped as soon as the patient begins to feel better.

Whether continued tocolysis after 48hours of rescue tocolysis improves neonatal outcome is unproven.To evaluate the effectiveness of maintenance tocolytic therapy with oral nifedipine on the reduction of adverse neonatal outcomes and the prolongation of pregnancy by performing an individual patient data meta - analysis (IPDMA).

Palos Community Hospital officials have maintained that the center is needed in the community because it would provide continuing care to patients who need cardiac rehabilitation, physical therapy and other specialized exercise programs.

It's vital that therapy / treatment be continued and not stopped as soon as the patient begins to feel better.

We are expanding care for the community by including OB / GYN, prenatal care, physical therapy, and outpatient lab services as well as continuing to provide leading primary care services through our NCQA level 3 Patient Centered Medical Home,»

We are expanding care for the community by including OB / GYN, prenatal care, physical therapy, and outpatient lab services as well as continuing to provide leading primary care services through our NCQA level 3 Patient Centered Medical Home,» said Joe McDonald, President and CEO for Catholic Health.

For example, would the p11 - boosting therapy — which incorporates into recipients» genetic code — continue to function even if a patient's depression has subsided after treatment?

The ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.

Moreover, the improvements stayed if the patient continued with the stimulation therapy, the researchers said.

Because so many of the patients in the early testing showed significant long - lasting responses, the study was continued and the FDA granted the drug «breakthrough therapy» status, allowing it to be fast - tracked for approval.

The team also continues efforts to adapt technologies that are accessible for patients around the world who don't have access to physical therapy centers with the latest equipment.

One of the biggest challenges that remains is making sure therapies continue to work with patients in the long term and pinpointing if that means cancer therapies should be administered in combination or deployed in a specific order for certain patients.

«This greater than expected survival in older patients selected for operative therapy is noteworthy,» said Dr. Fernandez, «especially considering that the prevalence of lung cancer is expected to increase as the population continues to grow older and more people survive into old age.»

Six months after completing therapy, 86 percent of the patients were alive with continued responses.

Use of cross-sex hormone therapy requires continued, shared decision making between patients and clinicians.

«We will continue to provide input to the FDA as the agency works to bring breakthrough therapies to patients that are clinically appropriate and effective, without compromising patients» health or safety.»

The data safety monitoring board of the trial, as mandated by the study protocol, continues to monitor outcomes in patients with a Recurrence Score of 11 to 25 randomized to chemo - endocrine therapy or endocrine therapy alone.

Researchers in US and Canada funded by the Cooperative Studies Program of the Department of Veterans Affairs and the Canadian Institutes for Health Research compared the costs and benefits of etanercept - methotrexate first versus triple therapy first in 353 patients enrolled in the RACAT trial who continued to have uncontrolled symptoms of RA after at least 12 weeks of methotrexate therapy.

After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 pTherapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 ptherapy and reduce the rate of relapse, which is about 50 percent.

Patients with metastatic colorectal cancer (mCRC) that are mutation - free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first - line chemotherapy and an anti-EGFR monoclonal antibody, according to study results (1) presented today at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

As these gene - editing therapies continue to develop and start to approach the clinic, it's important to make sure each therapy is going to be tailored to the patient that's going to be treated.»

By performing a genome - wide screen in breast cancer cells, Dr. Oesterreich and her colleagues identified a gene called HOXC10 as one that the cancer seems to modify to allow continued tumor growth in patients whose cancer becomes resistant to traditional therapies.

Professor Sterk commented: «We are living in an era where we have new biological knowledge and new targets for therapy but we largely continue to guide patient management with diagnostic labels.

Researchers in New Zealand studied 206 OA patients for two years to measure the efficacy of adding regular physical exercise, manual therapy, or a combination of both therapies to standard care, versus continuing usual medical care for OA alone.

Previous studies have shown a benefit in adding a second antiplatelet drug like ticagrelor, from a class called P2Y12 inhibitors, but they investigated the additional therapy for only a year, leaving unanswered the question of whether patients would benefit from continuing this treatment longer.

Patients on fixed - dose combination therapy are more likely to continue to take their pills and are more likely to take them as directed by their physician.

These are skills that we implement for other international trials of gene therapy for rare genetic diseases of the immune system, blood, muscle, vision or liver... We will continue the current study with the objective of providing treatment for patients.»

Current, standard VTE prevention techniques include the use of an elastic stocking and / or other external compression device upon admittance to the hospital, patient movement and rehabilitation beginning the first day after surgery and continuing for several months, and anticoagulant therapy (blood thinning medications) starting the night before surgery and continuing after the patient is discharged.

Despite legalization's substantial disruption to their industry, these businesses continued with their original identity focused on therapy and the patients, said Hsu.

But there's reason for optimism - recent advances in screening and treatment, such as CAR T cell therapy, mean patient outcomes and quality of life are continuing to improve.

In addition, the FDA will continue to work closely with industry to find other ways to aid in the effort to bring novel therapies to patients as quickly, and as safely, as possible.

Patients who respond to therapies might continue their course of care or transition to other therapies, including reduced - intensity bone marrow transplants.

Six patients had stem cell transplant, four are continuing study therapy, and one discontinued due to insurance issues.

He continues to investigate and optimize CAR T cell therapy, to make it more effective not only for blood cancers, but also to help patients with other types of cancer.

The persistence of the latent HIV reservoir in patients with HIV, well controlled on combination antiretroviral therapy (cART), is the reason why such patients currently need to continue lifelong treatment.

Years after receiving a single dose of gene therapy, patients on the hemophilia B trial continued to produce their own clotting factor from the normal transferred gene with minimal side effects.

In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.

Dr. Goldberg: But for many patients even with the entire arsenal of therapies that we have available to us today they continue to progress.

In the next year, members of the Dream Team will continue to study the tumor microenvironment before and after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of immune cells for adoptive cell therapy.

To build upon the encouraging early discoveries, Helmsley renewed and expanded its Crohn's funding for the Institute in 2013 to begin new work with three major aims: 1) continue studies of individual genes to determine how genetic differences between Crohn's patients and healthy individuals contribute to the disease; 2) evaluate promising small molecules in disease - relevant studies and prioritize insights from genetics to help develop novel therapeutics; and 3) begin basic experimentation in animal models with Crohn's disease to provide the data necessary to begin testing new therapies in humans.

All six patients were taking part in a clinical trial, and what was... Continue reading Visionary Science: Gene therapy saves sight thanks to animal research

Xavier and his team will also devote time to advancing their research by continuing to develop assays to screen molecules for potential therapies, study the microbiome, and compose a map of each cell in the gut in both healthy individuals and IBD patients.

Cancer is an extremely complex biological phenomenon showing enormous variability (e.g., age of patient, cell of origin, general health status, genetic background, location in an organ, nutritional status, presence or absence of continued development of neoplasia (i.e., carcinogenesis), presence or absence of enhancers, rate of growth and division, type and dosage of therapy administered, etc.).

Whether a doctor recommends surgery, chemotherapy, or therapies to reduce hormone production and slow tumor growth depends on the type and location of the tumor, if it is cancerous, and the patient's preferences, Dana - Farber continues.

«However, given the prevalence of depression, anxiety, and suicidal ideation / suicide in the general population, and especially the adolescent population who may be candidates for isotretinoin therapy,» state AAD guidelines for the use of the acne medication, «the prescribing physician should continue to monitor for these symptoms and make therapeutic decisions within the context of each individual patient.»